1. Lack of association of tumor-associated macrophages with clinical outcome in patients with classical Hodgkin's lymphoma
- Author
-
Irene Biasoli, Yasodha Natkunam, José Carlos Morais, Denize Azambuja, Matthew W. Anderson, I. S. Lossos, and Nelson Spector
- Subjects
Adult ,Male ,Oncology ,Epstein-Barr Virus Infections ,medicine.medical_specialty ,Pathology ,Adolescent ,Dacarbazine ,Antigens, Differentiation, Myelomonocytic ,Receptors, Cell Surface ,Kaplan-Meier Estimate ,Bleomycin ,Disease-Free Survival ,Young Adult ,chemistry.chemical_compound ,Antigens, CD ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Humans ,Progression-free survival ,In Situ Hybridization ,Aged ,Aged, 80 and over ,Tissue microarray ,business.industry ,Macrophages ,Original Articles ,Hematology ,Middle Aged ,Prognosis ,medicine.disease ,Hodgkin's lymphoma ,Hodgkin Disease ,Immunohistochemistry ,Chemotherapy regimen ,Vinblastine ,Lymphoma ,Treatment Outcome ,chemistry ,Tissue Array Analysis ,Female ,business ,medicine.drug - Abstract
Background: A recent study demonstrated that an increased number of CD68+ macrophages were correlated with primary treatment failure, shortened progression-free survival (PFS) and disease-specific survival (DSS) in patients with classical Hodgkin’s lymphoma (cHL). Patients and methods: The aim of the present study was to verify the relationship between the number of CD68+ and CD163+ macrophages with clinical outcomes in a cohort of 265 well-characterized patients with cHL treated uniformly with the standard doxorubicin, bleomycin, vinblastine and dacarbazine chemotherapy regimen. Two pairs of hematopathologists carried out independent pathological evaluations of tissue microarray slides. Results: There were no associations between clinical characteristics and the expression of CD68 or CD163. However, higher levels of CD68 and CD163 expression were correlated with the presence of Epstein‐Barr viruspositive Hodgkin tumor cells (P = 0.01 and 0.037, respectively). The expression of CD68 or CD163 was not associated with either the PFS or the DSS. Conclusion: CD68 and CD163 expression require further evaluation before their use can be recommended for prognostic stratification of patients with cHL.
- Published
- 2012
- Full Text
- View/download PDF